Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)

Conditions:   2019 Novel Coronavirus Disease;   2019 Novel Coronavirus Infection;   2019-nCoV Disease;   2019-nCoV Infection;   COVID-19;   COVID-19 Pandemic;   COVID-19 Virus Disease;   COVID-19 Virus Infection;   Covid19;   Coronavirus Disease 2019;   SARS-CoV2 Infection;   SARS-C oV-2 Acute Respiratory Disease Interventions:   Drug: Famotidine;   Drug: Celecoxib;   Drug: Placebo Sponsors:   Leidos Life Sciences;   United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials